(Q33631368)

28 July 2017

Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa (English)

1 reference

28 July 2017

1 reference

1 reference

parkinsonian syndrome

1 reference

2

Lees AJ

1 reference

28 July 2017

Hardie RJ

1

1 reference

PubMed ID

2900293

28 July 2017

language of work or name

English

0 references

publication date

1 June 1988

1 reference

Journal of Neurology, Neurosurgery and Psychiatry

28 July 2017

1 reference

28 July 2017

51

1 reference

28 July 2017

6

1 reference

28 July 2017

850-854

1 reference

Assessment of extrapyramidal disorders

28 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1033159

Drug-induced parkinsonism in the elderly

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1033159

Sustained levodopa therapy in tardive dyskinesia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1033159

The pathophysiology of extrapyramidal side-effects of neuroleptic drugs

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1033159

Effects of L-DOPA on pharmacological parkinsonism

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1033159

L-DOPA therapy in drug-induced parkinsonism evaluated by the method measuring the facial expression

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1033159

The action of L-dopa on schizophrenic patients (a preliminary report)

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1033159

Trial of Maintenance Therapy in Schizophrenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1033159

Effect of L-dopa in schizophrenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1033159

The abrupt withdrawal of antiparkinsonian drugs in schizophrenic patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1033159

Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1033159

Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine-induced Parkinsonism

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1033159

The Northwick Park Study of first episodes of schizophrenia. I. Presentation of the illness and problems relating to admission

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1033159

Drug induced parkinsonism

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1033159

Parkinson's disease in a Scottish city

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1033159

Extrapyramidal disturbances caused by inappropriate prescribing

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1033159

Parkinsonism, tardive dyskinesia, akathisia, and depression induced by flunarizine

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1033159

The motor disorders of severe psychiatric illness: a conflict of paradigms.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1033159

21 June 2018

L-Dopa and Schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1033159

Extrapyramidal side-effects of metoclopramide

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1033159

Assessment of drugs in schizophrenia. Discussion on assessment of drug- induced extrapyramidal reactions

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1033159

Assessment of drugs in schizophrenia. Asessment of drug-induced extrapyramidal reactions and of drugs given for their control

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1033159

Clinical effect of L-dopa on schizophrenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1033159

Psychomotility and parkinsonism in treatment with neuroleptic drugs.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1033159

Long-term effects of L-dopa and procyclidine on neuroleptic-induced extrapyramidal and schizophrenic symptoms

30 October 2018

1 reference

12 December 2020

Reversible drug-induced parkinsonism. Clinicopathologic study of two cases

1 reference

12 December 2020

L-dopa in depressed patients.

1 reference

12 December 2020

Behavioral effects of l-Dopa in schizophrenic patients

1 reference

12 December 2020

L-dopa challenge and relapse in schizophrenia

1 reference

12 December 2020

Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. III. Relapse postponement or relapse prevention? The implications for long-term outcome

1 reference

12 December 2020

Action of L-Dopa in drug induced extrapyramidalism

1 reference

12 December 2020

A survey of drug-induced extrapyramidal reactions

1 reference

12 December 2020

1 reference

12 December 2020

Headache and the eye. A community study

1 reference

12 December 2020

Prolonged drug-induced Parkinsonism

1 reference

12 December 2020

Identifiers

DOI

10.1136/JNNP.51.6.850

1 reference

28 July 2017

1 reference

28 July 2017

1 reference

PubMed ID

2900293